Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.

Margaret Hellard, Alisa Pedrana, Bridget Draper

Abstract readComment

In one paragraph

Article in The lancet. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C.Tropical medicine and infectious disease · 2024
Article

4 · The record

Corrections and comments

Comment on
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.2021

5 · Who and what money

Authors and funding

3 authors.

Margaret HellardDisease Elimination Program, Burnet Institute, Melbourne 3004, VIC, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Doherty Institute and School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. Electronic address: margaret.hellard@burnet.edu.au.

Alisa PedranaDisease Elimination Program, Burnet Institute, Melbourne 3004, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Bridget DraperDisease Elimination Program, Burnet Institute, Melbourne 3004, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis CHepatitis C, ChronicBenzimidazolesHumansLiver CirrhosisSofosbuvirValineBenzimidazolesravidasvirSofosbuvirValine

Identifiers

PMID33865506

DOI10.1016/S2468-1253(21)00135-7

PMCPMC9259283

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.